<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02088021</url>
  </required_header>
  <id_info>
    <org_study_id>CL07045</org_study_id>
    <nct_id>NCT02088021</nct_id>
  </id_info>
  <brief_title>Assessment of the St. Jude Medical PorticoTM Re-sheathable Aortic Valve System - Alternative Access</brief_title>
  <acronym>PorticoALTEU</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical investigation is to evaluate the use of the Portico ALC Delivery
      System to place a transcatheter aortic valve through an alternative access site, specifically
      subclavian/axillary or TAo.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Business decision
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Vascular Complications related to the Portico ALC Delivery System</measure>
    <time_frame>30 day post procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>30 day post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Rates</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Event rates as described by VARC-2
&quot;Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document European Heart Journal (2012) 33, 2403-2418.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional improvement from baseline</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Functional improvement from baseline as compared to 30 days by:
NYHA Functional Classification
Six Minute Walk Test
Effective Orifice Area (EOA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute device success</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Acute device success defined as:
Ability of the Portico ALC Delivery System to successfully deliver, deploy, and resheath (if necessary) a transcatheter aortic valve
Absence of procedural mortality
Correct positioning of a single prosthetic heart valve into the proper anatomical location
Intended performance of the prosthetic heart valve, as defined by:
mean aortic valve gradient &lt;20 mmHg or peak velocity &lt;3 m/s, and
no moderate or severe prosthetic valve regurgitation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Symptomatic Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Portico Transcatheter Aortic Valve Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placement of the SJM Portico aortic valve with a ALC delivery system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Portico Transcatheter Aortic Valve</intervention_name>
    <description>Placement of the SJM Portico aortic valve with a ALC delivery system</description>
    <arm_group_label>Portico Transcatheter Aortic Valve Implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has provided written informed consent.

          -  Subject is 65 years of age or older at the time of index procedure, and/or has
             comorbidities that, in the opinion of the Principal Investigator or the Subject
             Selection Committee, preclude surgical valve replacement.

          -  Subject's aortic annulus diameter meets the range indicated in the Instructions for
             Use as measured by multislice CT conducted within 120 days prior to the index
             procedure.

          -  Subject has senile degenerative aortic stenosis with echocardiography within 30 days
             of index procedure as defined by at least 1 of the following:

               -  derived mean gradient greater than 40 mmHg, OR

               -  jet velocity greater than 4.0 m/s, OR

               -  aortic valve area of less than 0.8 cm2, OR

               -  aortic valve area index less than or equal to 0.6 cm2/m2.

          -  Subject has symptomatic aortic stenosis as demonstrated by NYHA Functional
             Classification of II, III, or IV.

          -  Subject is deemed high operable risk and delivery route is suitable for TAVI per the
             medical opinion of the Subject Selection Committee.

          -  Subject's predicted operative mortality or serious, irreversible morbidity risk is
             less than 50% at 30 days post index procedure.

        Exclusion Criteria:

          -  Subject is unwilling or unable to comply with all study-required follow-up
             evaluations.

          -  Subject has a documented history of a cerebral vascular accident (CVA) or transient
             ischemic attack (TIA) within 6 months (less than or equal to 180 days) prior to the
             index procedure.

          -  Subject has carotid artery disease requiring intervention.

          -  Evidence of an acute myocardial infarction (MI) within 30 days prior to patient
             providing consent (defined as: ST Segment Elevation as evidenced on 12 Lead ECG).

          -  Subject has a native aortic valve that is congenitally unicuspid, bicuspid,
             quadricuspid or non-calcified as seen by echocardiography.

          -  Subject has mitral valvular regurgitation greater than grade III.

          -  Subject has moderate or severe mitral stenosis.

          -  Subject has a pre-existing prosthetic cardiac device, valve, or prosthetic ring in any
             position.

          -  Subject refuses any blood product transfusion.

          -  Subject refuses surgical valve replacement.

          -  Subject has left ventricular ejection fraction (LVEF) less than 20%.

          -  Subject has documented, untreated symptomatic coronary artery disease (CAD) requiring
             revascularization.

          -  Subject has had a percutaneous interventional or other invasive cardiovascular or
             peripheral vascular procedure less than or equal to 14 days of index procedure.

          -  Subject has severe basal septal hypertrophy that would interfere with transcatheter
             aortic valve placement.

          -  Subject has a history of, or is currently diagnosed with endocarditis.

          -  There is imaging evidence of intracardiac mass, thrombus, or vegetation.

          -  Subject is considered hemodynamically unstable (requiring inotropic support or
             mechanical heart assistance).

          -  Subject is in acute pulmonary edema or requiring intravenous diuretic therapy to
             stabilize heart failure.

          -  Subject with significant pulmonary disease as determined and documented by the
             Investigator.

          -  Subject has significant chronic steroid use as determined and documented by the
             Investigator.

          -  Subject has a documented hypersensitivity or contraindication to anticoagulant or
             antiplatelet medication.

          -  Subject has renal insufficiency as evidenced by a serum creatinine greater than 3.0
             mg/dL (265.5 µmol/L) or end-stage renal disease requiring chronic dialysis.

          -  Subject has morbid obesity defined as a BMI greater than or equal to 40.

          -  Subject has ongoing infection or sepsis.

          -  Subject has blood dyscrasias (eg, leukopenia, acute anemia, thrombocytopenia, history
             of bleeding diathesis, or coagulopathy).

          -  Subject has a current autoimmune disease that, in the opinion of the Principal
             Investigator or the Subject Selection Committee, precludes the subject from study
             participation.

          -  Significant ascending aortic disease documented by diameter greater than 40mm.

          -  Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within 90
             days prior to the index procedure.

          -  Subject is currently participating in another investigational drug or device study.

          -  Subject requires emergency surgery for any reason.

          -  Subject has a life expectancy less than 12 months.

          -  Subject has other medical, social or psychological conditions that, in the opinion of
             the Principal Investigator or the Subject Selection Committee, preclude the subject
             from study participation.

          -  Subject is diagnosed with dementia or admitted to a chronic care facility which would
             fundamentally complicate rehabilitation from the procedure or compliance with
             follow-up visits.

          -  Subject is unwilling or unable to comply with all study-required follow-up
             evaluations.

          -  Subject has a documented history of a cerebral vascular accident (CVA) or transient
             ischemic attack (TIA) within 6 months (less than or equal to 180 days) prior to the
             index procedure.

          -  Subject has carotid artery disease requiring intervention.

          -  Evidence of an acute myocardial infarction (MI) within 30 days prior to patient
             providing consent (defined as: ST Segment Elevation as evidenced on 12 Lead ECG).

          -  Subject has a native aortic valve that is congenitally unicuspid, bicuspid,
             quadricuspid or non-calcified as seen by echocardiography.

          -  Subject has mitral valvular regurgitation greater than grade III.

          -  Subject has moderate or severe mitral stenosis.

          -  Subject has a pre-existing prosthetic cardiac device, valve, or prosthetic ring in any
             position.

          -  Subject refuses any blood product transfusion.

          -  Subject refuses surgical valve replacement.

          -  Subject has left ventricular ejection fraction (LVEF) less than 20%.

          -  Subject has documented, untreated symptomatic coronary artery disease (CAD) requiring
             revascularization.

          -  Cardiovascular or peripheral vascular procedure less than or equal to 14 days of index
             procedure.

          -  Subject has severe basal septal hypertrophy that would interfere with transcatheter
             aortic valve placement.

          -  Subject has a history of, or is currently diagnosed with endocarditis.

          -  There is imaging evidence of intracardiac mass, thrombus, or vegetation.

          -  Subject is considered hemodynamically unstable (requiring inotropic support or
             mechanical heart assistance).

          -  Subject is in acute pulmonary edema or requiring intravenous diuretic therapy to
             stabilize heart failure.

          -  Subject with significant pulmonary disease as determined and documented by the
             Investigator.

          -  Subject has significant chronic steroid use as determined and documented by the
             Investigator.

          -  Subject has a documented hypersensitivity or contraindication to anticoagulant or
             antiplatelet medication.

          -  Subject has renal insufficiency as evidenced by a serum creatinine greater than 3.0
             mg/dL (265.5 µmol/L) or end-stage renal disease requiring chronic dialysis.

          -  Subject has morbid obesity defined as a BMI greater than or equal to 40.

          -  Subject has ongoing infection or sepsis.

          -  Subject has blood dyscrasias (eg, leukopenia, acute anemia, thrombocytopenia, history
             of bleeding diathesis, or coagulopathy).

          -  Significant ascending aortic disease documented by diameter greater than 40mm.

          -  Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within 90
             days prior to the index procedure.

          -  Subject is currently participating in another investigational drug or device study.

          -  Subject requires emergency surgery for any reason.

          -  Subject has a life expectancy less than 12 months.

          -  Subject has other medical, social or psychological conditions that, in the opinion of
             the Principal Investigator or the Subject Selection Committee, preclude the subject
             from study participation.

          -  Subject is diagnosed with dementia or admitted to a chronic care facility which would
             fundamentally complicate rehabilitation from the procedure or compliance with
             follow-up visits.

          -  Subject has a documented allergy to contrast media, nitinol alloys, porcine tissue, or
             bovine tissue.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Linke, Prof Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heartcenter Leipzig GmbH</affiliation>
  </overall_official>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2014</study_first_submitted>
  <study_first_submitted_qc>March 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2014</study_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

